Simon Quick Advisors LLC Has $758,000 Position in Novo Nordisk A/S (NYSE:NVO)

Simon Quick Advisors LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 63.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,918 shares of the company's stock after purchasing an additional 4,241 shares during the period. Simon Quick Advisors LLC's holdings in Novo Nordisk A/S were worth $758,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Center for Financial Planning Inc. raised its position in Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after buying an additional 123 shares during the last quarter. Strategic Investment Solutions Inc. IL raised its position in Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after buying an additional 300 shares during the last quarter. Park Square Financial Group LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at approximately $29,000. Transce3nd LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at approximately $33,000. Finally, CX Institutional acquired a new stake in Novo Nordisk A/S in the 1st quarter valued at approximately $36,000. Institutional investors own 11.54% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on NVO. BNP Paribas began coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Finally, Dbs Bank lowered Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of "Hold" and a consensus price target of $112.00.

Novo Nordisk A/S Stock Down 1.4%

Shares of NYSE:NVO traded down $1.15 during trading on Friday, hitting $79.90. 7,465,072 shares of the company were exchanged, compared to its average volume of 7,042,462. The stock has a market cap of $358.57 billion, a price-to-earnings ratio of 24.29, a P/E/G ratio of 0.90 and a beta of 0.66. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The firm has a fifty day moving average price of $67.30 and a two-hundred day moving average price of $79.63. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. The firm had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.